Insmed Inc (INSM)vsNeuphoria Therapeutics Inc (NEUP)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NEUP
Neuphoria Therapeutics Inc
$4.37
-3.10%
HEALTHCARE · Cap: $24.85M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 3946% more annual revenue ($606.42M vs $14.99M). INSM leads profitability with a -2.1% profit margin vs -37.8%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NEUP
Avoid35
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM is growing revenue faster at 1.5% — sustainability is the question.
NEUP generates stronger free cash flow (-6M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is an innovative biotechnology company devoted to developing pioneering therapies for mental health disorders, utilizing psychedelic compounds and advanced drug delivery technologies. With a strong focus on translating cutting-edge research into effective treatments for significant unmet needs in the mental health sector, Neuphoria is establishing itself as a leader in this rapidly evolving industry. The company boasts a robust pipeline of preclinical candidates, making it an attractive investment opportunity for institutional investors seeking to capitalize on the next wave of biotech innovations. Neuphoria's commitment to delivering transformative therapeutic solutions positions it as a key player in redefining the future of mental health care.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?